Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONKOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus BRONKOSOL.
AQUAPHYLLIN vs BRONKOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Renal: 90-95% unchanged; biliary/fecal: <5%.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Bronchodilator
Bronchodilator